Development of specific Kinase Inhibitors for the Treatment of Inflammatory diseases

被引：0
|
作者：
Neubauer, G. [1 ]
机构：
[1] Cellzome, Heidelberg, Germany
来源：
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2012年 / 62卷
关键词：
MECHANISMS; CELLS;
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：S18 / S19
页数：2
相关论文
共 50 条
  • [21] JAK inhibitors for the treatment of autoimmune and inflammatory diseases
    Jamilloux, Yvan
    El Jammal, Thomas
    Vuitton, Lucine
    Gerfaud-Valentin, Mathieu
    Kerever, Sebastien
    Seve, Pascal
    [J]. AUTOIMMUNITY REVIEWS, 2019, 18 (11)
  • [22] The Synthesis and Testing of Rho Kinase Inhibitors Reversibly Coupled to Corticosteroids for the Treatment of Ocular Inflammatory Diseases
    deLong, Mitchell
    Kelly, Curtis
    Crews, Karen
    Sturdivant, Jill
    Glendenning, Angie
    Foley, Briana
    Clancy, Daphne
    Germann, Monica
    White, Jeff
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [23] Hit to lead campaign of a series of cyclobutenediones as MAPKAP kinase 2 inhibitors for the treatment of inflammatory diseases
    Sabalski, Joan E.
    Banker, Annette L.
    Resnick, Lynn O.
    Butera, John A.
    Czerwinski, Robert
    Kirincich, Steven J.
    Lovering, Frank E.
    McFadyen, Ian J.
    Lin, Lih-Ling
    Liu, J.
    Parris, Kevin
    Svenson, Kristine
    Telliez, Jean-Baptiste
    Wang, Weiheng
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [24] Possibility of development of Rho kinase inhibitors for cardiovascular diseases
    Seto, Minoru
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 : 11P - 11P
  • [25] Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
    Nash, Peter
    Kerschbaumer, Andreas
    Doerner, Thomas
    Dougados, Maxime
    Fleischmann, Roy M.
    Geissler, Klaus
    McInnes, Iain
    Pope, Janet E.
    van der Heijde, Desiree
    Stoffer-Marx, Michaela
    Takeuchi, Tsutomu
    Trauner, Michael
    Winthrop, Kevin L.
    de Wit, Maarten
    Aletaha, Daniel
    Baraliakos, Xenofon
    Boehncke, Wolf-Henning
    Emery, Paul
    Isaacs, John D.
    Kremer, Joel
    Lee, Eun Bong
    Maksymowych, Walter P.
    Voshaar, Marieke
    Tam, Lai-Shan
    Tanaka, Yoshiya
    van den Bosch, Filip
    Westhovens, Rene
    Xavier, Ricardo
    Smolen, Josef S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (01) : 71 - 87
  • [26] Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases
    Wohlrab, Johannes
    Kegel, Thomas
    Grosse, Regina
    Eichner, Adina
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 (08): : 845 - 851
  • [27] Structure-activity relationships of phosphatidylinositol-3-kinase δ inhibitors for the treatment of inflammatory respiratory diseases
    Garces, Aimie
    Schwehm, Carolin
    Stocks, Michael
    Kindon, Nicholas
    MacDonald, Simon
    Rowedder, James
    Bradshaw, Tracey
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [28] Progress in the discovery of kinase inhibitors for treatment of parasitic diseases
    Rotella, David
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [29] Novel Rho Kinase Inhibitors with Bronchodilator and Anti-inflammatory Properties Suitable for Treatment of Respiratory Diseases
    Navratil, Tomas
    Wells, Grace
    Fulcher, Emilee
    Sorensen, Scott
    Bodnar, Wanda
    Crean, Chris
    Lampe, John
    Peterson, Ward
    [J]. FASEB JOURNAL, 2009, 23
  • [30] Kinase targets and inhibitors for the treatment of airway inflammatory diseases - The next generation of drugs for severe asthma and COPD?
    Adcock, IM
    Caramori, G
    [J]. BIODRUGS, 2004, 18 (03) : 167 - 180
12345